# Undetected Neuromuscular Disease in Patients after Heart Transplantation

**Authors:** Biniam Melese Bekele, Elisabetta Gazzerro, Felix Schoenrath, Volkmar Falk, Simone Rost, Selina Hoerning, Yvonne Jelting, Ann-Kathrin Zaum, Simone Spuler, Jan Knierim

PMC · DOI: 10.3390/ijms25147819 · International Journal of Molecular Sciences · 2024-07-17

## TL;DR

Some heart transplant patients may have undiagnosed neuromuscular diseases that affect both heart and muscle function.

## Contribution

This study identifies genetic causes of muscle weakness in heart transplant patients using exome sequencing and clinical assessments.

## Key findings

- Seven out of 39 patients reported new-onset muscle weakness and motor limitations.
- Three patients had genetic variants in genes related to muscle function like nexilin, myosin heavy chain, and SPG7.
- 10% of patients showed clinical signs of myopathy potentially due to genetic causes.

## Abstract

(1) Heart transplantation (HTX) improves the overall survival and functional status of end-stage heart failure patients with cardiomyopathies (CMPs). The majority of CMPs have genetic causes, and the overlap between CMPs and inherited myopathies is well documented. However, the long-term outcome in skeletal muscle function and possibility of an undiagnosed underlying genetic cause of both a cardiac and skeletal pathology remain unknown. (2) Thirty-nine patients were assessed using open and standardized interviews on muscle function, a quality-of-life (EuroQol EQ-5D-3L) questionnaire, and a physical examination (Medical Research Council Muscle scale). Whole-exome sequencing was completed in three stages for those with skeletal muscle weakness. (3) Seven patients (17.9%) reported new-onset muscle weakness and motor limitations. Objective muscle weakness in the upper and lower extremities was seen in four patients. In three of them, exome sequencing revealed pathogenic/likely pathogenic variants in the genes encoding nexilin, myosin heavy chain, titin, and SPG7. (4) Our findings support a positive long-term outcome of skeletal muscle function in HTX patients. However, 10% of patients showed clinical signs of myopathy due to a possible genetic cause. The integration of genetic testing and standardized neurological assessment of motor function during the peri-HTX period should be considered.

## Linked entities

- **Genes:** NEXN (nexilin F-actin binding protein) [NCBI Gene 101789628], bt (bent) [NCBI Gene 43814], SPG7 (SPG7 matrix AAA peptidase subunit, paraplegin) [NCBI Gene 6687]
- **Diseases:** cardiomyopathies (MONDO:0004994)

## Full-text entities

- **Genes:** SPG7 (SPG7 matrix AAA peptidase subunit, paraplegin) [NCBI Gene 6687] {aka CAR, CMAR, PGN, SPG5C}, NEXN (nexilin F-actin binding protein) [NCBI Gene 91624] {aka CDM2M, CMH20, NELIN}, TTN (titin) [NCBI Gene 7273] {aka CMD1G, CMH9, CMPD4, CMYO5, CMYP5, EOMFC}
- **Diseases:** cardiac and skeletal pathology (MESH:D006331), CMPs (MESH:D009202), muscle weakness (MESH:D018908), inherited myopathies (MESH:D030342), end-stage heart failure (MESH:D007676), motor limitations (MESH:D045745), HTX (OMIM:605376), myopathy (MESH:D009135), Undetected Neuromuscular Disease (MESH:D009468)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11277526/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11277526/full.md

## References

64 references — full list in the complete paper: https://tomesphere.com/paper/PMC11277526/full.md

---
Source: https://tomesphere.com/paper/PMC11277526